Evidence map›Paper›PMID 40561798›Full record

ArticleTranslational oncology2025

miR-23b is a negative regulator of tumor suppressing PTPRG in colorectal cancer.

Hong Duan, Jianhu Jia, Tingting Wang, Ghulam Jilany Khan, Li Wang, Sirong Zhang, Jianhua Yang, Chenghui He, Fei Li, Henggui Hu and 1 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Translational oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Hong DuanEngineering Research Center for Development and High Value Utilization of Genuine Medicinal Materials in North Anhui Province, School of Biological and Food Engineering, Suzhou University, Suzhou, Anhui, 234000, China; College of Pharmacy, Xinjiang Medical University, Urumqi, 830000, China.
Jianhu JiaEngineering Research Center for Development and High Value Utilization of Genuine Medicinal Materials in North Anhui Province, School of Biological and Food Engineering, Suzhou University, Suzhou, Anhui, 234000, China; College of Pharmacy, Xinjiang Medical University, Urumqi, 830000, China.
Tingting WangEngineering Research Center for Development and High Value Utilization of Genuine Medicinal Materials in North Anhui Province, School of Biological and Food Engineering, Suzhou University, Suzhou, Anhui, 234000, China; College of Pharmacy, Xinjiang Medical University, Urumqi, 830000, China.
Ghulam Jilany KhanDepartment of Pharmacology and Therapeutics, Faculty of Pharmacy, University of Central Punjab, Lahore 54000, Pakistan.
Li WangEngineering Research Center for Development and High Value Utilization of Genuine Medicinal Materials in North Anhui Province, School of Biological and Food Engineering, Suzhou University, Suzhou, Anhui, 234000, China; College of Pharmacy, Xinjiang Medical University, Urumqi, 830000, China.
Sirong ZhangEngineering Research Center for Development and High Value Utilization of Genuine Medicinal Materials in North Anhui Province, School of Biological and Food Engineering, Suzhou University, Suzhou, Anhui, 234000, China; College of Pharmacy, Xinjiang Medical University, Urumqi, 830000, China.
Jianhua YangCollege of Pharmacy, Xinjiang Medical University, Urumqi, 830000, China.
Chenghui HeCollege of Pharmacy, Xinjiang Medical University, Urumqi, 830000, China.
Fei LiCollege of Pharmacy, Xinjiang Medical University, Urumqi, 830000, China; State Key Laboratory of Natural Medicines, China Pharmaceutical University, Nanjing, 210009, China. Electronic address: lifei@cpu.edu.cn.
Henggui HuGeneral Clinical Research Center, Anhui Wanbei Coal-Electricity Group General Hospital, Suzhou 234000, China. Electronic address: huhenggui@163.com.
Kefeng ZhaiEngineering Research Center for Development and High Value Utilization of Genuine Medicinal Materials in North Anhui Province, School of Biological and Food Engineering, Suzhou University, Suzhou, Anhui, 234000, China; College of Pharmacy, Xinjiang Medical University, Urumqi, 830000, China. Electronic address: kefengzhai@163.com.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Colorectal cancer (CRC) is among top most common cancers with high mortality rate and major health issue yet to resolve across the globe. miR-23b is an oncogene in many cancers including CRC. The route of involvement of miR-23b in the regulation of CRC is still unclear. Study explored bioregulatory mechanism of miR-23b against CRC involving in vitro and animal model experimentation via experimentation involving ki67 immunohistochemistry, CCK8, EDU, and Transwell cell migration. The bioinformatic studies were employed to predict miR-23b target tumor suppressor PTPRG while the luciferase reporter gene assay was used to find the binding capabilities of miR-23b to the 3'-UTR of PTPRG. The changes in the expression of miR-23b were found in three CRC cell lines including SW480, HT29, and Caco2, and their correlation with PTPRG protein were assessed through western blot and RT-PCR. Moreover, the association of PTPRG gene in the SW480 cell on CRC by CCK8, EDU, and Transwell cell migration assay. Furthermore, we also detected the PTPRG protein levels in clinical samples of the tissues. Afterwards, the regulatory involvement PTPRG through miR-23b was studied by means of co-overexpression in both animals based and cell-based studies. CRC growth is associated with miR-23b and directly targets the PTPRG in CRC cells. PTPRG may restrict the cell proliferation and migration and can restore the miR-23b mediated CRC growth. MiR-23b is directly linked with the CRC development via PTPRG restriction suggesting miR-23b as novel therapeutic target against CRC.

Indexed as

Colorectal cancerMigrationmiR-23bProliferationPTPRG

Identifiers

PMID40561798
PMCPMC12240168

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.